Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
September 30, 2026 19.77M
June 30, 2026 15.54M
March 31, 2026 9.652M
December 31, 2025 5.760M
September 30, 2025 5.569M
June 30, 2025 6.531M
March 31, 2025 9.094M
December 31, 2024 11.90M
September 30, 2024 14.64M
June 30, 2024 16.19M
March 31, 2024 14.22M
December 31, 2023 12.71M
September 30, 2023 11.17M
June 30, 2023 10.10M
March 31, 2023 12.34M
December 31, 2022 14.65M
September 30, 2022 30.21M
June 30, 2022 32.35M
March 31, 2022 33.74M
December 31, 2021 32.04M
September 30, 2021 16.84M
June 30, 2021 16.97M
March 31, 2021 17.22M
December 31, 2020 22.04M
September 30, 2020 28.01M
Date Value
June 30, 2020 33.05M
March 31, 2020 35.60M
December 31, 2019 39.12M
September 30, 2019 38.61M
June 30, 2019 37.30M
March 31, 2019 38.05M
December 31, 2018 34.89M
September 30, 2018 32.42M
June 30, 2018 33.01M
March 31, 2018 31.09M
December 31, 2017 30.26M
September 30, 2017 30.21M
June 30, 2017 27.11M
March 31, 2017 22.68M
December 31, 2016 20.44M
September 30, 2016 20.20M
June 30, 2016 18.18M
March 31, 2016 19.95M
December 31, 2015 18.53M
September 30, 2015 15.24M
June 30, 2015 36.15M
March 31, 2015 46.22M
December 31, 2014 42.85M
September 30, 2014 40.04M
June 30, 2014 15.50M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Heron Therapeutics, Inc. 11.93M
Tonix Pharmaceuticals Holding Corp. 80.40M
Karyopharm Therapeutics, Inc. 120.81M
Corbus Pharmaceuticals Holdings, Inc. 103.65M
Ocugen, Inc. 45.12M